Treatment of Temporomandibular Joint Syndrome in Juvenile Idiopathic Arthritis

This protocol addresses active temporomandibular joint (TMJ) arthritis occurring in patients with juvenile idiopathic arthritis (JIA) — a specific and clinically important subset requiring targeted management guided by rheumatology guidelines.

Clinical Scenario

In patients with juvenile idiopathic arthritis, the temporomandibular joint is a recognised site of active arthritis. Management of TMJ involvement in this population follows dedicated recommendations from major rheumatology bodies, as the underlying inflammatory disease shapes treatment choices.

Treatment Approach

The structured regimen for this scenario involves biologic disease-modifying antirheumatic drugs (DMARDs) as a key therapeutic class. Full eligibility criteria, sequencing, and agent selection are outlined in the complete protocol…

Instant Access to Structured Evidence-Based Regimens

References

A guideline from the American College of Rheumatology includes recommendations for the treatment of active TMJ arthritis in patients with juvenile idiopathic arthritis.

Consider biologic DMARDs for patients with an inadequate response to or intolerance of NSAIDs and/or intra-articular glucocorticoids and at least one conventional synthetic DMARD.

View source ↗